Six days after a startling trial halt, AstraZeneca gets a green light to resume dosing their Oxford Covid-19 vaccine –


Six days after an abrupt and startling halt of their late-stage study of the Oxford vaccine for Covid-19, AstraZeneca is back in business. And we also learned on Saturday that Pfizer and BioNTech are boosting the size of their fast-running Phase III, with plans to add 14,000 people to the

Sourced through from: